Executives of Da Vinci Robot Developer Sell Shares Worth $3 Million Amidst Significant Stock Vesting

Intuitive Surgical Inc. (ISRG), a U.S. robotic surgery company, disclosed that its Chief Medical Officer and its Senior Vice President of Manufacturing and Supply Chain sold company shares under Rule 10b5-1 trading plans in late February and early March, and also reported transactions related to RSU vesting and tax withholdings.

On February 27, EVP and Chief Medical Officer Myriam Curet sold approximately 2,345 shares held in a trust, generating about $1.2 million (roughly KRW 1.5 billion) in cash. Two days later, a substantial number of shares were automatically withheld to cover taxes when her restricted stock units and performance shares converted to common stock.

Between March 3 and 5, SVP of Manufacturing and Supply Chain Mark Brosius sold a total of 3,658 shares in three separate transactions, raising about $1.8 million (around KRW 2.4 billion). After these sales, his direct holdings fell to roughly 2,900 shares.

In early March, the company completed its acquisition of a partner’s distribution unit for the da Vinci and Ion platforms in Southern Europe—covering Italy, Spain, and Portugal—bringing about 250 employees into its direct-sales organization and formally launching full commercial operations in the region.

In its January 22 announcement of fourth-quarter fiscal 2025 results, Intuitive Surgical reported revenue of approximately $2.9 billion (about KRW 3.8 trillion) and net income of around $800 million (roughly KRW 1 trillion), marking double-digit year-over-year growth. The company also set a global target of 13–15% growth in da Vinci procedures for 2026.

Headquartered in Sunnyvale, California, Intuitive Surgical specializes in minimally invasive surgical robots, best known for its da Vinci Surgical System and the Ion bronchoscopic platform. The da Vinci robot has led the market by replacing laparoscopic procedures in urology, gynecology, and general surgery. The company is expanding a subscription-based revenue model—driven by consumables and service contracts—tied to its installed base and procedure volumes.